These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2955770)

  • 1. No D2 receptor increase in PET study of schizophrenia.
    Farde L; Wiesel FA; Hall H; Halldin C; Stone-Elander S; Sedvall G
    Arch Gen Psychiatry; 1987 Jul; 44(7):671-2. PubMed ID: 2955770
    [No Abstract]   [Full Text] [Related]  

  • 2. Kinetic analysis of receptor binding with positron emission tomography.
    Eriksson L; Farde L; Rosenquist G
    Acta Radiol Suppl; 1991; 376():126-7. PubMed ID: 1666746
    [No Abstract]   [Full Text] [Related]  

  • 3. Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride.
    Seeman P; Niznik HB; Guan HC
    Arch Gen Psychiatry; 1990 Dec; 47(12):1170-2. PubMed ID: 2244801
    [No Abstract]   [Full Text] [Related]  

  • 4. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
    Farde L; Wiesel FA; Stone-Elander S; Halldin C; Nordström AL; Hall H; Sedvall G
    Arch Gen Psychiatry; 1990 Mar; 47(3):213-9. PubMed ID: 1968328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain dopamine receptors in schizophrenia: PET problems.
    Seeman P
    Arch Gen Psychiatry; 1988 Jun; 45(6):598-600. PubMed ID: 3259865
    [No Abstract]   [Full Text] [Related]  

  • 6. Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Seeman P
    Neuropsychopharmacology; 1992 Aug; 7(1):55-7; discussion 73-5. PubMed ID: 1388022
    [No Abstract]   [Full Text] [Related]  

  • 7. PET studies of neuroreceptors in schizophrenia. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Wong DF
    Neuropsychopharmacology; 1992 Aug; 7(1):69-72; discussion 73-5. PubMed ID: 1388023
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [11C]SCH 23390 and [11C]raclopride.
    Farde L
    Psychopharmacology (Berl); 1992; 107(1):23-9. PubMed ID: 1534178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography of brain dopamine D-2 receptors with 11C-raclopride in early Parkinson's disease.
    Laihinen A; Rinne JO; Någren K; Bergman J; Haaparanta M; Solin O; Ruotsalainen U; Rinne UK
    Acta Radiol Suppl; 1991; 376():151. PubMed ID: 1666759
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of two PET radioligands for imaging extrastriatal dopamine receptors in the human brain.
    Wang GJ; Volkow ND; Fowler JS; Wolf AP; MacGregor RR; Shea CE; Schlyer DJ; Hitzemann RJ
    Synapse; 1993 Nov; 15(3):246-9. PubMed ID: 8278901
    [No Abstract]   [Full Text] [Related]  

  • 12. Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis.
    Farde L; Eriksson L; Blomquist G; Halldin C
    J Cereb Blood Flow Metab; 1989 Oct; 9(5):696-708. PubMed ID: 2528555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.
    Hietala J; Syvälahti E; Vuorio K; Någren K; Lehikoinen P; Ruotsalainen U; Räkköläinen V; Lehtinen V; Wegelius U
    Arch Gen Psychiatry; 1994 Feb; 51(2):116-23. PubMed ID: 7905257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D2 receptors in normal human brain: effect of age measured by positron emission tomography (PET) and [11C]-raclopride.
    Antonini A; Leenders KL
    Ann N Y Acad Sci; 1993 Sep; 695():81-5. PubMed ID: 8239318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain.
    Seeman P; Guan HC; Niznik HB
    Synapse; 1989; 3(1):96-7. PubMed ID: 2521961
    [No Abstract]   [Full Text] [Related]  

  • 18. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.
    Kaasinen V; Ruottinen HM; Någren K; Lehikoinen P; Oikonen V; Rinne JO
    J Nucl Med; 2000 Jan; 41(1):65-70. PubMed ID: 10647606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.
    Farde L; Hall H; Ehrin E; Sedvall G
    Science; 1986 Jan; 231(4735):258-61. PubMed ID: 2867601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo.
    Pohjalainen T; Rinne JO; Någren K; Syvälahti E; Hietala J
    Am J Psychiatry; 1998 Jun; 155(6):768-73. PubMed ID: 9619148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.